Synergy's (SGYP) Plecanatide Seen as 'Rare Gem' at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Synergy Pharmaceuticals' (SGYP) Buy Rating and $16 PT Reiterated at Rodman & Renshaw
April 20, 2016 7:34 AM EDTRodman & Renshaw reiterated a Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) with a price target of $16. Analyst Raghuram Selvaraju said he is highly confident in plecanatide's prospects.
"Early yesterday, Synergy Pharmaceuticals announced that the FDA had accepted its New Drug Application (NDA) for the... More
BTIG Affirms Synergy Pharma (SGYP) at 'Buy'; Believes Plecanatide Potential Largely Being Ignored
April 19, 2016 11:41 AM EDTBTIG reaffirms Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) at Buy wth a price target of $11 after the company announced that the U.S. Food and Drug Administration (FDA) has determined that the companys New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the... More
Synergy Pharma's (SGYP) Plecanatide NDA Accepted for Review by U.S. FDA; PDUFA Date Set
April 19, 2016 6:02 AM EDTSynergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced the U.S. Food and Drug Administration (FDA) has determined that the companys New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
"This is a transformative milestone for our company and reflects our relentless commitment to bringing meaningful treatment options to patients suffering from... More
Allergan (AGN) Takeover of Synergy Pharmaceuticals (SGYP) May be Imminent - Source
April 15, 2016 3:13 PM EDTAllergan (NYSE: AGN) is in advanced talks to acquire Synergy Pharmaceuticals (Nasdaq: SGYP), according to a source claiming to have knowledge of the situation. The two sides could announce a deal as soon as next... More
